CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 224 enrolled
Drug / intervention
Caelyx (Pegylated Lyposomal Doxorubicin)drug
Likely dose
Caelyx (Pegylated Lyposomal Doxorubicin) 50 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00743431
NCT00743431N/ACompleted
CompareCT.gov

Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (PPE).

Merck Sharp & Dohme LLC·observational·Posted Aug 28, 2008·Updated Apr 15, 2015

In Brief

An observational study evaluating Caelyx (Pegylated Lyposomal Doxorubicin) for Ovarian Neoplasms. Completed, enrolled 224 participants.

Detailed Summary

The purpose of this study is to evaluate the safety and tolerability of Caelyx in women with advanced ovarian cancer, focusing on infusion reactions and palmar-plantar erythrodysesthesia.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Neoplasms
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 28, 2008
Enrollment StartFeb 1, 2005
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 17.8 years ago

Interventions

Caelyx (Pegylated Lyposomal Doxorubicin)drug

Pegylated Lyposomal Doxorubicin, 50 mg/m2 every 4 weeks for 6 cycles.